News
Sanofi tightens grip on RSV, paying $1.15B upfront for Vicebio and boosting its pipeline beyond mRNA
Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclinical and phase 1 vaccine ...
France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...
Sanofi Consumer Healthcare said its growth was driven by successful product launches and the successful relaunch of two ...
For now, Sanofi’s U.S. inventory is insulating the company from a potential 15% tariff on drugs shipped from the EU.
4h
Capital Market on MSNSanofi Consumer Healthcare spurts after Q2 results
Sanofi Consumer Healthcare India surged 12.56% to Rs 5385 after the company announced strong financial results for the second quarter of 2025.
Sanofi India's demerged entity, Sanofi Consumer Healthcare India, has reported a 28% year-on-year increase in Q2 revenue at ...
The pharmaceutical company’s top line grew faster than analysts expected for the second quarter due to drug launches and ...
French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...
Sanofi Consumer Healthcare India reports ₹220 crore revenue, ₹60 crore profit, driven by exports, product launches, and ...
France's Sanofi said on Thursday that it expects annual sales to grow by high single-digit percentage, helped by strong ...
By Bhanvi Satija (Reuters) -Drugmaker Sanofi said on Thursday it believes the impact from U.S. tariffs to be manageable as it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results